|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

* Departamento de Análises Clínicas e Toxicológicas, Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brazil
Faculdade de Ciências Farmacêuticas, and Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brazil
Published, JLR Papers in Press, July 1, 2003. DOI 10.1194/jlr.M200467-JLR200
1 To whom correspondence should be addressed. e-mail: dspa{at}usp.br
| ABSTRACT |
|---|
|
|
|---|
The presence of this novel nitrogen-containing lipid product in human plasma and lipoproteins could represent a potential indicator of the oxidative/nitrative roles that NO or its metabolites play during in vivo lipid oxidation, generating a compensatory mechanism of protection in vascular disease.
Abbreviations: Ch18:2, cholesteryl linoleate (cholesteryl 9,12-octadecadienoate); Ch18:2NO2, cholesteryl nitrolinoleate; [3H]-Ch18:2, [1
,2
(n)-3H]cholesteryl linoleate; IR, infrared; LC-ESI/MS/MS, liquid chromatography/electrospray ionization tandem mass spectrometry; LONO, nitritelinoleate; LONO2, nitratelinoleate; NO2, nitrogen dioxide radical
Supplementary key words nitration cholesteryl linoleate lipoproteins mass spectrometry
| INTRODUCTION |
|---|
|
|
|---|
Nitrated lipid formation has also been shown in a variety of in vitro model systems, including unsaturated free fatty acids, phosphatidylcholine liposomes, LDL oxidized by copper, endothelial cells, and macrophages (69). This formation can be primarily a consequence of NO or its metabolites reacting with lipid-derived radicals (e.g., L, LO, LOO) via diffusion-limited rates (109 to 1011 mol/l-1/s-1) (10, 11) leading to the formation of nitrated products with structural characteristics of nitrolinoleate, nitritelinoleate (LONO), nitratelinoleate (LONO2), L(O)NO2, and nitrohydroxylinoleate (1218). Nitrolipids can also be formed by a direct reaction of NO2 with nonoxidized lipids at physiological pH (16), or by a reaction of nitrous acid (HONO) (Reaction 2), a product yielded by nitrite acidification, with oxidized lipids (16, 18). At physiological pH, e.g., 7.4, NO2- is reasonably stable. However, in an acidic media, as in inflammatory states, gastric compartment, and neutrophil phagocytic vesicles, NO2- equilibrates with HONO (pKa = 3.25), which, in turn, is readily converted to a range of potent nitrosating/nitrating species, such as NO2
ONOO- + H+
ONOOH
OH + NO2
Reaction 1
NO2- + H
HONO
Reaction 2
2 HONO
N2O3 + H2O
Reaction 3
N2O3
NO + NO2
Reaction 4
and N2O3, (Reactions 3, 4) capable of inducing modifications of polyunsaturated fatty acids (18).
Recent studies have demonstrated the presence of these products in biological samples. A vicinal nitrohydroxy arachidonate derivative was detected in bovine coronary arteries, which spontaneously releases NO, causing relaxation in rat coronary aorta rings (19). Nitrolinoleate and its nitrohydroxy derivative, nitrohydroxylinoleate, were detected in human blood plasma (20). Moreover, some studies have demonstrated biological activities of these nitrated products, such as endothelium independent vasorelaxation (19, 21), inhibition of platelet aggregation (22), and antinflamatory actions, such as inhibition of superoxide generation, neutrophil degranulation, and integrin expression (23), suggesting that these nitrated lipids could have vascular-protective effects.
In the present work, for the first time, is reported the presence of cholesteryl nitrolinoleate (Ch18:2NO2), a stable cholesteryl linoleate (Ch18:2)-derived nitrated product, in human blood plasma and lipoproteins, using high-pressure liquid chromatography coupled to electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS). The ex vivo detection of these products represents an important step in the understanding of the protective and/or deleterious effects of in vivo modified lipoproteins on blood vessels.
| MATERIALS AND METHODS |
|---|
|
|
|---|
,2
(n)-3H] Ch18:2 was obtained from Amersham (Buckinghamshire, UK). tert-Butanol and chromatographic-grade methanol were obtained from Merck (Gibbstown, NJ). All other reagents were from Sigma Chemical Co. (St. Louis, MO).
Nitration of Ch18:2
A solution of Ch18:2 (0.07 mmol) in chloroform (2 ml) was purged with nitrogen, and solid NO2BF4 was added (0.12 mmol). The mixture was kept under nitrogen atmosphere at room temperature for 1 h, and then 1 ml of 0.1 M phosphate buffer, pH 7.4 was added. The organic layer was separated, dried, and redissolved in 1 ml of 2-propanol. To isolate the nitrated lipids, the extract was passed through a 2.5 cm x 5.5 cm silica gel (200400 mesh) column equilibrated with hexane. Nitrated lipids were separated from Ch18:2 with a hexane-diethyl ether step gradient (5% increments from 0 to 20% of diethyl ether). The content of nitrated lipid in the eluted fraction was monitored by thin-layer chromatography (TLC) using a mixture of methanol-chloroform (1:1; v/v) as solvent. Lipid fraction (1 µl) was applied to RP-18 F254s 5 x 10 cm TLC plates (Merck KgaA, Darmstadt, Germany), where the separated lipid components were detected with iodine. Fractions containing mainly nitrated lipids were separated, dried under a vacuum, redissolved in 2-propanol, maintained at -20°C, and analyzed by LC-ESI/MS/MS. Nitration was also done by adding sodium [15N]nitrite (0.1 mmol) to 0.10 mmol of Ch18:2 in 200 µl chloroform-methanol (2:1; v/v) following acidification to pH 3.0 with 1 N HCl and incubation at 25°C for 15 min under aerobic conditions. One milliliter of 0.1 M, pH 7.4, phosphate buffer was added, and extraction was done with 5 ml of diethyl ether. The organic layer was separated, dried, and maintained at -20°C until LC-ESI/MS/MS analysis.
Structural and quantitative analyses of nitrated lipids by LC-ESI/MS/MS and infrared spectroscopy
Mass spectrometry analysis was performed on a Quattro II triple quadrupole mass spectrometer (Micromass, Manchester, UK) following reversed-phase HPLC on a 20 x 4.0 mm id, 4 µ, Mercury MS column (Phenomenex, Torrance, CA) using an isocratic system with methanol-tert-butanol (3:1; v/v) containing 10 mM of ammonium acetate as mobile phase at a flow rate of 0.4 ml/min. The column eluent was totally inserted into the ion spray interface. Positive ion mass spectra were recorded with an orifice potential of 20 V. The source temperature was kept at 100°C. Daughter ion and multiple reaction monitoring (MRM) mass spectra were obtained with a collision energy of 10 eV or 20 eV, respectively, and gas (Ar) pressure at 6.0 x10-4 mbar. The full scan was made at an interval between m/z 40 and 800. The nitrated product was detected in MRM mode as ammonium adduct [M+NH4]+, selecting the ions of m/z 711 in the first and 369 in the third quadrupole (m/z 711
369). The MRM transition for Ch18:2 and 3H-labeled cholesteryl linoleate (3H-Ch18:2) were also measured as m/z 666
369 and m/z 668
371, respectively. This detection mode was used to increase the specificity of the analysis. Quantitative yields of nitrated product (Ch18:2NO2) were calculated by elemental analysis of nitrogen content using a chemiluminescent nitrogen detector (Sievers® NOA 280, Boulder, CO) using sodium nitrite as standard. The data obtained for Ch18:2NO2 were used for its quantification in the LC-ESI/MS/MS system. A calibration curve was also performed with Ch18:2. The lipid residue obtained after treatment of Ch18:2 with NO2BF4 was used for infrared (IR) analysis. IR spectra were obtained with a Bomem MB 100 spectrometer by accumulating 32 scans between 400 and 4,000 cm-1.
LDL isolation and lipid extraction
Human blood from four normolipidemic subjects (cholesterol <200 mg/dl) was collected after overnight fasting in tubes containing ethyldiaminetetraacetic acid (EDTA). Plasma was obtained after blood centrifugation at 2,500 rpm for 10 min at 4°C, and antiprotease inhibitors and antioxidants were immediately added to avoid lipoprotein degradation. Lipoproteins were separated from plasma by sequential ultracentrifugation using a Sorvall® Ultra Pro 80 (Sorvall Products L.P., Newtown, CT) and dialyzed against Tris buffer, pH 7.4, (150 mM NaCl, 1.0 mM EDTA, 3 mM NaN3, and 10 mM Tris) for 12 h. Lipid extraction from VLDL, LDL, and/or HDL was done by mixing 1 ml of each lipoprotein fraction with 500 µl of methanol, with vortex stirring for 30 s. Then 5 ml of hexane-diethyl ether (80:20; v/v) containing 0.02% butylated hydroxytoluene, previously treated with Chelex® to avoid further lipid oxidation during lipid extraction, was added. Samples were vortexed (2 min) and centrifuged at 2,500 rpm for 5 min at 4°C. The upper layer was collected, filtered (0.22 µ), and evaporated to dryness in a vacuum rotary evaporator. Lipids were dissolved in 100 µl of tert-butanol-methanol (1:1; v/v), and then 10 µl was immediately injected into a LC-ESI/MS/MS system using the protocol described for the standards. The same extraction system was used in the blood plasma analyses. To verify a possible artifactual nitration of Ch18:2 during the handling of the samples, the extraction procedure was also performed by the addition of an internal standard 3H-labeled Ch18:2 in plasma (100 pmol in chloroform), which can also be followed by LC-ESI/MS/MS.
| RESULTS |
|---|
|
|
|---|
369 ion (Fig. 2)
. The Ch18:2 used in the synthesis yielded
70% of Ch18:2NO2.
|
|
|
369 was found. Moreover, the m/z 711 ion showed a fragmentation pattern and retention time identical to those of products synthesized by the reaction of Ch18:2 with NO2BF4 or NO2- in acid pH [Fig. 4A
(trace a), B]. The product with m/z 711 that fragments in m/z 369 was detected in LDL (Fig. 5)
, as well as in VLDL and HDL samples (data not shown). The addition of [3H]-Ch18:2 to samples before the extraction procedure did not yield the [3H]-Ch18:2 nitrated product. This is indicated by the absence of a molecular ion of m/z 713 that fragments in a daughter ion of m/z 371 [Fig. 4A (trace b)].
|
|
14.0 min. It appears as an ion with m/z 666, relative to ammonium adduct [M+NH4]+, that fragments given a main daughter ion of m/z 369, characteristic of the cholesteryl group (Fig. 6A, B)
. The [3H]-Ch18:2 added to plasma samples, which has the same retention time as Ch18:2 (Fig. 6C), appears as a molecular ion of m/z 668 [M+NH4]+, which fragments given a main ion of m/z 371 (Fig. 6D), characteristic of [3H]-labeled cholesterol [([3H]-cholesterol)-OH]+. The nitrated product represents
0.26% of the total of plasmatic Ch18:2, maintaining practically the same proportion in different lipoproteins (Fig. 7)
. The concentrations observed in plasma samples (mean ± SD, n = 4) were 76.9 ± 10.7 (nmol/l) and 30 ± 8.7 (µmol/l) for Ch18:2NO2 and Ch18:2, respectively.
|
|
| DISCUSSION |
|---|
|
|
|---|
|
50 carbons, such as Ch18:2 (26). The increase of one mass unit using [15N]nitrite confirms that the ion contains one nitrogen atom per molecule and is compatible with the nitrated Ch18:2 structure. This evidence was reinforced by IR analyses of the nitrated product, as compared with Ch18:2, that showed novel bands at 1,549 and 1,373 cm-1, corresponding to the N = O binding of RNO2 (27). These results clearly showed that the product formed in this synthesis is Ch18:2NO2. It was not possible to determine the position of the nitro group in the carbon chain of the fatty acid. It is possible that a mixture of stereo and positional isomers (i.e., at C9, C10, C12, or C13 and/or cis-trans isomers) is formed that is not possible to discriminate by mass spectrometry analysis. The analysis of blood plasma and lipoproteins showed an ion with m/z 666, characteristic of the Ch18:2 ammonium adduct, as previously described (28). Ch18:2 was chosen because it is the predominant lipid component in the LDL core (28) and linoleic acid (18:2) is the most abundant polyunsaturated fatty acid in human blood plasma (29). As the presence of double-bonded carbons is an initial condition for NO2 attack (18), polyunsaturated fatty acids would be suitable substrates for NO2-mediated nitration. Fragmentation of the ion with m/z 666 showed a main daughter ion with m/z 369, characteristic of the cholesteryl group, as previously described (28).
Products given molecular ions with m/z 711, showing the same chromatographic characteristics and fragmentation pattern as those of synthesized standards, were found in human blood plasma and lipoproteins of normolipidemic donors. A possible artifactual nitration that could occur during the extraction procedure was tested by adding [3H]-labeled Ch18:2 to plasma samples. As the corresponding nitrated [3H]-Ch18:2 was not detected, an artifactual nitration during sample workup was excluded. The possibility that azide contributes to nitration was also excluded, because azide was used only for isolation of lipoproteins and not for plasma samples. Small differences in MS/MS fragmentation spectra patterns between synthesized standards and products of plasma or lipoproteins could be explained by the presence of different positional isomers and/or functional group orientation (e.g., -NO2 or -ONO) in vivo. Furthermore, the possibility cannot be excluded that Ch18:2-ONO (cholesteryl nitritelinoleate) could be formed in vivo and decomposed by transnitrozation or other routes during sample extraction and workup.
Nitrated lipids present in plasma and lipoproteins can be considered as potential indicators of the chain-breaking antioxidant role of NO during lipid peroxidation, as previously reported (7, 8, 11), indicating that reactions of NO, or its derivatives, with lipids may be important in vivo. Due to its relative hydrophobicity, NO readily diffuses into hydrophobic lipid membranes, greatly increasing its local concentration (30). This property significantly increases the chain-breaking efficiency of low concentrations of NO, favoring lipid peroxidation inhibition. Nitrated lipids could also be formed in vivo in the lipid microenvironments where the rate of NO autoxidation is high (e.g., with concurrent NO and O2 therapy during lung disease) or where high NO2- concentrations are combined with low pH (e.g., gastric compartment, phagolysosome, and ischemic events) (16, 18).
In the context of hypercholesterolemia, we recently described increased levels of nitrated linoleic acid derivatives in plasma of hyperlipidemic compared with normolipidemic subjects (20). These could be implicated in the formation of reactive nitrogen species during plasma and/or tissue oxidative damage in hyperlipidemia. In fact, enhancement of NO production during hypercholesterolemia has been associated with low NO bioactivity (3136). It is also well known that the increase of oxidative stress in hypercholesterolemia (3739) implicated in the generation of reactive oxygen species could contribute to the formation of nitrated species in the vascular wall. Therefore, the presence of nitrated lipids in plasma can be an indicator of the inhibitory role of NO in lipid oxidation, and/or a footprint of the presence of oxidants/nitrating agents in the vascular system. Finally, whereas it is suggested that these nitrated lipids cause vasorelaxation by NO release (19, 21) and have other beneficial effects in the atherothrombotic process, such as inhibition of platelet aggregation and antiinflamatory actions (22, 23), we postulate that the presence of these nitrated products in vivo would indicate primarily a storage form of NO acting as a compensatory mechanism for the impaired endothelial-dependent vasorelaxation characteristic of the early steps of vascular disease.
| ACKNOWLEDGMENTS |
|---|
Manuscript received December 13, 2002 and in revised form June 4, 2003.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Miersch, M. G. Espey, R. Chaube, A. Akarca, R. Tweten, S. Ananvoranich, and B. Mutus Plasma Membrane Cholesterol Content Affects Nitric Oxide Diffusion Dynamics and Signaling J. Biol. Chem., July 4, 2008; 283(27): 18513 - 18521. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. S. Baker, P. R. S. Baker, F. Golin-Bisello, F. J. Schopfer, M. Fink, S. R. Woodcock, B. P. Branchaud, R. Radi, and B. A. Freeman Nitro-fatty Acid Reaction with Glutathione and Cysteine: KINETIC ANALYSIS OF THIOL ALKYLATION BY A MICHAEL ADDITION REACTION J. Biol. Chem., October 19, 2007; 282(42): 31085 - 31093. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Cui, F. J. Schopfer, J. Zhang, K. Chen, T. Ichikawa, P. R. S. Baker, C. Batthyany, B. K. Chacko, X. Feng, R. P. Patel, et al. Nitrated Fatty Acids: Endogenous Anti-inflammatory Signaling Mediators J. Biol. Chem., November 24, 2006; 281(47): 35686 - 35698. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Wright, F. J. Schopfer, P. R. S. Baker, V. Vidyasagar, P. Powell, P. Chumley, K. E. Iles, B. A. Freeman, and A. Agarwal Fatty acid transduction of nitric oxide signaling: Nitrolinoleic acid potently activates endothelial heme oxygenase 1 expression. PNAS, March 14, 2006; 103(11): 4299 - 4304. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. S. Baker, F. J. Schopfer, S. Sweeney, and B. A. Freeman From the Cover: Red cell membrane and plasma linoleic acid nitration products: Synthesis, clinical identification, and quantitation PNAS, August 10, 2004; 101(32): 11577 - 11582. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |